Should chronic HBV infected patients with normal ALT treated: Debate

Hepatology International

Volumn 2, Issue 2, 2008, Pages 179-184

  Sarin, Shiv Kumar ^a   Kumar, Manoj ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

ALT; Chronic Hepatitis B

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLACEBO; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; BACTERIAL PERITONITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; ESOPHAGUS VARICES; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MEDICAL RESEARCH; NONHUMAN; ONSET AGE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SEROCONVERSION; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 55249085911     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9065-2     Document Type: Review

References (41)

1. 1. R Franchis de A Hadengue G Lau D Lavanchy A Lok N McIntyre 2003 EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version) J Hepatol. 39 Suppl 1 S3 25 14708673 de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39(Suppl 1):S3–25.
2. 2. SL Tsai PJ Chen MY Lai PM Yang JL Sung JH Huang 1992 Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens: implications for hepatitis B e antigen seroconversion J Clin Invest. 89 87 96 1729285 10.1172/JCI115590 1:CAS:528:DyaK38Xlslahtg%3D%3D Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens: implications for hepatitis B e antigen seroconversion. J Clin Invest. 1992;89:87–96.
3. 3. YS Hsu RN Chien CT Yeh IS Sheen HY Chiou CM Chu 2002 Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology. 35 1522 7 12029639 10.1053/jhep.2002.33638 Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.
4. 4. SJ Hadziyannis D Vassilopoulos 2001 Hepatitis B e antigen-negative chronic hepatitis B Hepatology. 34 617 24 11584355 10.1053/jhep.2001.27834 1:STN:280:DC%2BD3Mrjs1Srug%3D%3D Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–24.
5. 5. MR Brunetto F Oliveri B Coco G Leandro P Colombatto JM Gorin 2002 Outcome of anti-HBe positive chronic hepatitis B in alpha–interferon treated and untreated patients: a long term cohort study J Hepatol. 36 263 70 11830339 10.1016/S0168-8278(01)00266-5 1:CAS:528:DC%2BD38Xit1eis7s%3D Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha–interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263–70.
6. 6. M Manno C Camma F Schepis F Bassi R Gelmini F Giannini 2004 Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years Gastroenterology. 127 756 63 15362032 10.1053/j.gastro.2004.06.021 Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756–63.
7. 7. YC Chen IS Sheen CM Chu YF Liaw 2002 Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection Gastroenterology. 123 1084 9 12360470 10.1053/gast.2002.36026 Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–9.
8. 8. CL Lai V Ratziu MF Yuen T Poynard 2003 Viral hepatitis B Lancet. 362 2089 94 14697813 10.1016/S0140-6736(03)15108-2 1:CAS:528:DC%2BD3sXpvFylsb4%3D Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–94.
9. 9. CM Chu SJ Hung J Lin DI Tai YF Liaw 2004 Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels Am J Med. 116 829 34 15178498 10.1016/j.amjmed.2003.12.040 1:CAS:528:DC%2BD2cXkslWltLs%3D Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–34.
10. 10. MF Yuen HJ Yuan DK Wong JC Yuen WM Wong AO Chan 2005 Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications Gut. 54 1610 4 15871997 10.1136/gut.2005.065136 Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.
11. 11. DA Shafritz D Shouval HI Sherman SJ Hadziyannis MC Kew 1981 Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens N Engl J Med. 305 1067 73 6268980 1:STN:280:DyaL38%2FhtlGgtw%3D%3D 10.1056/NEJM198110293051807 Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067–73.
12. 12. D Prati E Taioli A Zanella E Della Torre S Butelli E Vecchio Del 2002 Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern Med. 137 1 9 12093239 1:CAS:528:DC%2BD38Xls1entbc%3D Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–9.
13. 13. C Puoti A Magrini T Stati P Rigato F Montagnese P Rossi 1997 Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels Hepatology. 26 1393 8 9397976 10.1002/hep.510260603 1:STN:280:DyaK1c%2FlvVGrtw%3D%3D Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393–8.
14. 14. A Piton T Poynard F Imbert-Bismut L Khalil J Delattre E Pelissier 1998 Factors associated with serum alanine transaminase activity in healthy patients: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group Hepatology. 27 1213 9 9581673 10.1002/hep.510270505 1:CAS:528:DyaK1cXjtVSjsbk%3D Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy patients: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213–9.
15. 15. HC Kim CM Nam SH Jee KH Han DK Oh I Suh 2004 Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study BMJ. 328 983 8 15028636 10.1136/bmj.38050.593634.63 1:CAS:528:DC%2BD2cXksFOmtbs%3D Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983–8.
16. 16. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen 2006 The risk evaluation of viral load elevation and associated liver disease/cancer Gastroenterology. 130 678 86 16530509 10.1053/j.gastro.2005.11.016 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. The risk evaluation of viral load elevation and associated liver disease/cancer. Gastroenterology. 2006;130:678–86.
17. 17. G Ricci C Bac De F Caramia 1973 Carriers of hepatitis B antigen: an epidemiologic and histologic study J Infect Dis. 128 125 8 4198022 1:STN:280:DyaE3s3hslKgtg%3D%3D Ricci G, De Bac C, Caramia F. Carriers of hepatitis B antigen: an epidemiologic and histologic study. J Infect Dis. 1973;128:125–8.
18. 18. E Tapp DM Jones D Hollanders IW Dymock 1976 Serial liver biopsies in blood donors with persistent HBs antigenaemia J Clin Pathol. 29 884 6 977761 10.1136/jcp.29.10.884 1:STN:280:DyaE2s%2FivFaltQ%3D%3D Tapp E, Jones DM, Hollanders D, Dymock IW. Serial liver biopsies in blood donors with persistent HBs antigenaemia. J Clin Pathol. 1976;29:884–6.
19. 19. B Dragosics P Ferenci E Hitchman H Denk 1987 Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases Hepatology. 7 302 6 3557309 10.1002/hep.1840070215 1:STN:280:DyaL2s7mtl2htQ%3D%3D Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7:302–6.
20. 20. R Franchis de A D’Arminio M Vecchi G Ronchi E Ninno Del A Parravicini 1980 Chronic asymptomatic HBsAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV Gastroenterology. 79 521 7 7429112 de Franchis R, D’Arminio A, Vecchi M, Ronchi G, Del Ninno E, Parravicini A, et al. Chronic asymptomatic HBsAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV. Gastroenterology. 1980;79:521–7.
21. 21. CL Lin LY Liao CJ Liu MW Yu PJ Chen MY Lai 2007 Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels Hepatology. 45 5 1193 8 17464993 10.1002/hep.21585 1:CAS:528:DC%2BD2sXlslOju7o%3D Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology. 2007;45(5):1193–8.
22. 22. J Li GM Zhao LM Zhu Y Li SJ Xin 2007 Liver pathological changes and clinical features of patients with chronic hepatitis B virus infection in their immune tolerant phase and non-active status Zhonghua Gan Zang Bing Za Zhi. 15 5 326 9 17524261 Li J, Zhao GM, Zhu LM, Li Y, Xin SJ. Liver pathological changes and clinical features of patients with chronic hepatitis B virus infection in their immune tolerant phase and non-active status. Zhonghua Gan Zang Bing Za Zhi. 2007;15(5):326–9.
23. 23. M Lai BJ Hyatt I Nasser M Curry NH Afdhal 2007 The clinical significance of persistently normal ALT in chronic hepatitis B infection J Hepatol. 47 6 760 7 17928090 10.1016/j.jhep.2007.07.022 1:CAS:528:DC%2BD2sXht12ns7bI Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760–7.
24. 24. EB Keeffe DT Dieterich SH Han RM Jacobson P Martin ER Schiff 2006 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update Clin Gastroenterol Hepatol. 4 936 62 16844425 10.1016/j.cgh.2006.05.016 1:CAS:528:DC%2BD28XptFWmtrg%3D Keeffe EB, Dieterich DT, Han SH, Jacobson RM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–62.
25. 25. CJ Chen MW Yu YF Liaw 1997 Epidemiological characteristics and risk factors of hepatocellular carcinoma J Gastroenterol Hepatol. 12 S294 308 9407350 10.1111/j.1440-1746.1997.tb00513.x 1:STN:280:DyaK1c%2FntFansw%3D%3D Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–308.
26. 26. CJ Chen HI Yang J Su CL Jen SL You SM Lu 2006 REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA. 295 65 73 16391218 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SM, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
27. 27. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff 2004 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States Clin Gastroenterol Hepatol. 2 87 106 15017613 10.1016/S1542-3565(03)00312-4 1:CAS:528:DC%2BD2cXitlOkt78%3D Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87–106.
28. 28. MF Yuen HJ Yuan DK Wong JC Yuen WM Wong AO Chan 2005 Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications Gut. 54 1610 4 15871997 10.1136/gut.2005.065136 Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.
29. 29. H Mommeja-Marin E Mondou MR Blum F Rousseau 2003 Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature Hepatology. 37 1309 19 12774009 10.1053/jhep.2003.50208 Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309–19.
30. 30. JL Dienstag RD Goldin EJ Heathcote HW Hann M Woessner SL Stephenson 2003 Histological outcome during long-term lamivudine therapy Gastroenterology. 124 105 17 12512035 10.1053/gast.2003.50013 1:CAS:528:DC%2BD3sXot1antQ%3D%3D Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17.
31. 31. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto 2005 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med. 352 2673 81 15987916 10.1056/NEJMoa042957 1:CAS:528:DC%2BD2MXls1Sksbc%3D Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–81.
32. 32. CL Lai D Shouval AS Lok TT Chang H Cheinquer Z Goodman 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med. 354 1011 20 16525138 10.1056/NEJMoa051287 1:CAS:528:DC%2BD28XitFWlsrY%3D Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.
33. 33. TT Chang RG Gish R Man de A Gadano J Sollano YC Chao 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med. 354 1001 10 16525137 10.1056/NEJMoa051285 1:CAS:528:DC%2BD28XitFWms7Y%3D Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.
34. 34. YF Liaw JJ Sung WC Chow G Farrel CZ Lee H Yuen 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med. 351 1521 31 15470215 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D Liaw YF, Sung JJ, Chow WC, Farrel G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.
35. 35. Yuen MF, Seto WK, Chow DHF, Tsui K, Wong DKH, Chan P, et al. Long-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy. Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, California. Abstract 985.
36. 36. DR Averett WS Mason 1995 Evaluation of drugs for antiviral activity against hepatitis B virus Viral Hepatitis Rev. 1 129 42 Averett DR, Mason WS. Evaluation of drugs for antiviral activity against hepatitis B virus. Viral Hepatitis Rev. 1995;1:129–42.
37. 37. MF Yuen DKH Wong SS Sum HJ Yuan JC Yuen AO Chan 2005 Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection Am J Gastroenterol. 100 1099 103 15842584 10.1111/j.1572-0241.2005.41530.x 1:CAS:528:DC%2BD2MXkvVSms7c%3D Yuen MF, Wong DKH, Sum SS, Yuan HJ, Yuen JC, Chan AO, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1099–103.
38. 38. B Werle-Lapostolle S Bowden S Locarnini K Wursthom J Petersen G Lav 2004 Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology. 126 1750 8 15188170 10.1053/j.gastro.2004.03.018 1:CAS:528:DC%2BD2cXlsFaqs78%3D Werle-Lapostolle B, Bowden S, Locarnini S, Wursthom K, Petersen J, Lav G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.
39. 39. DKH Wong MF Yuen VWS Ngai J Fung CL Lai 2006 One-year entecavir or lamivudine therapy results in reduction of HBV intrahepatic covalently closed circular DNA levels Antiviral Ther. 11 7 909 16 1:CAS:528:DC%2BD28Xhtlajs7rN Wong DKH, Yuen MF, Ngai VWS, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of HBV intrahepatic covalently closed circular DNA levels. Antiviral Ther. 2006;11(7):909–16.
40. 40. K Wursthorn M Lutgehetmann M Dandri T Volz P Buggisch B Zollner 2006 Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology. 44 3 675 84 16941693 10.1002/hep.21282 1:CAS:528:DC%2BD28XhtVeqt7bM Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84.
41. 41. AD Enriquez MS Campbell KR Reddy 2007 Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis Aliment Pharmacol Ther. 26 3 383 91 17635373 1:STN:280:DC%2BD2svhvVOhsA%3D%3D 10.1111/j.1365-2036.2007.03382.x Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther. 2007;26(3):383–91.